Published in Nephrol Dial Transplant on June 24, 2008
Adherence to prescribed oral medication in adult patients undergoing chronic hemodialysis: a critical review of the literature. Eur J Med Res (2009) 1.25
Update and critical appraisal of sevelamer in the management of chronic renal failure. Open Access J Urol (2010) 1.13
Pharmacology, efficacy and safety of oral phosphate binders. Nat Rev Nephrol (2011) 1.02
Phosphate binding therapy in dialysis patients: focus on lanthanum carbonate. Ther Clin Risk Manag (2008) 0.96
Hyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherence. BMC Nephrol (2013) 0.84
New therapies: calcimimetics, phosphate binders and vitamin D receptor activators. Pediatr Nephrol (2010) 0.81
Dissociation between progression of coronary artery calcification and endothelial function in hemodialysis patients: a prospective pilot study. Clin Nephrol (2012) 0.81
Differential effects of phosphate binders on pre-dialysis serum bicarbonate in end-stage kidney disease patients on maintenance haemodialysis. BMC Nephrol (2013) 0.79
Contemporary management of phosphorus retention in chronic kidney disease: a review. Clin Exp Nephrol (2015) 0.76
Phosphate binders in patients with chronic kidney disease. Aust Prescr (2017) 0.75
Hyperphosphatemia. The hidden killer in chronic kidney disease. Saudi Med J (2015) 0.75
Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol (2004) 11.23
Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int (2005) 3.56
Chronic kidney disease and cognitive impairment in the elderly: the health, aging, and body composition study. J Am Soc Nephrol (2005) 3.14
Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract (2005) 1.76
Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis (2003) 1.52
Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis (1997) 1.48
Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol (2006) 1.31
Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clin Nephrol (2004) 1.22
Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study. Nephron Clin Pract (2005) 1.15
Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. Nat Clin Pract Endocrinol Metab (2007) 1.14
Absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate. J Clin Pharmacol (2006) 1.05
Calcium acetate control of serum phosphorus in hemodialysis patients. Am J Kidney Dis (1991) 0.99
Hyperphosphatemia: pharmacologic intervention yesterday, today and tomorrow. Clin Nephrol (2000) 0.90
Pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis (1994) 0.88
Lanthanum carbonate for the treatment of hyperphosphataemia in renal failure and dialysis patients. Expert Opin Pharmacother (2005) 0.86
Lanthanum carbonate--a first line phosphate binder? Semin Dial (2007) 0.79
Calcium carbonate as phosphate binder in dialysis. Lancet (1987) 0.79
Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study. Am J Kidney Dis (2007) 2.47
Intradialytic parenteral nutrition does not improve survival in malnourished hemodialysis patients: a 2-year multicenter, prospective, randomized study. J Am Soc Nephrol (2007) 2.18
A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines on acute kidney injury: part 1: definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant (2012) 1.94
Low protein diets for chronic kidney disease in non diabetic adults. Cochrane Database Syst Rev (2009) 1.31
Early impairment of trabecular microarchitecture assessed with HR-pQCT in patients with stage II-IV chronic kidney disease. J Bone Miner Res (2010) 1.16
Dialyzer membrane permeability and survival in hemodialysis patients. Am J Kidney Dis (2005) 1.15
Contrast-induced nephropathy and its prevention: What do we really know from evidence-based findings? J Nephrol (2009) 1.09
Malnutrition in hemodialysis diabetic patients: evaluation and prognostic influence. Kidney Int (2002) 1.02
Interstitial expression of alpha-SMA: an early marker of chronic renal allograft dysfunction. Nephrol Dial Transplant (2002) 1.01
Neither perceived job stress nor individual cardiovascular reactivity predict high blood pressure. Hypertension (2003) 0.97
Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach. J Hypertens (2004) 0.96
Evolution of renal oxygen content measured by BOLD MRI downstream a chronic renal artery stenosis. Nephrol Dial Transplant (2010) 0.95
C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis. Nephrol Dial Transplant (2011) 0.93
The relationship between adipokines, osteocalcin and bone quality in chronic kidney disease. Nephrol Dial Transplant (2009) 0.89
Treatment options for IgA nephropathy in adults: a proposal for evidence-based strategy. Nephrol Dial Transplant (2004) 0.89
Hemodynamic responses to acute and gradual renal artery stenosis in pigs. Am J Hypertens (2010) 0.89
Toward green dialysis: focus on water savings. Hemodial Int (2013) 0.88
Validation of renal oxidative metabolism measurement by positron-emission tomography. Hypertension (2007) 0.86
Ischemia induces early expression of a new transcription factor (6A3-5) in kidney vascular smooth muscle cells: studies in rat and human renal pathology. Am J Pathol (2003) 0.83
Incidence of nephrogenic systemic fibrosis in patients undergoing dialysis after contrast-enhanced magnetic resonance imaging with gadolinium-based contrast agents: the Prospective Fibrose Nephrogénique Systémique study. Invest Radiol (2014) 0.83
Is hypertension a tissue perfusion disorder? Implications for renal and myocardial perfusion. J Hypertens Suppl (2006) 0.83
Predicted creatinine clearance to evaluate glomerular filtration rate in black Caribbean subjects. Nephrol Dial Transplant (2003) 0.83
The spectrum of renal involvement in patients with inflammatory myopathies. Medicine (Baltimore) (2014) 0.81
Renal perfusion: noninvasive measurement with multidetector CT versus fluorescent microspheres in a pig model. Radiology (2011) 0.81
Impact of prior CKD management in a renal care network on early outcomes in incident dialysis patients: a prospective observational study. BMC Nephrol (2013) 0.80
Postconditioning with cyclosporine a reduces early renal dysfunction by inhibiting mitochondrial permeability transition. Transplantation (2015) 0.79
[Direct medical cost of erythropoiesis-stimulating agents in anaemia treatment of chronic renal failure patient: a literature review]. Nephrol Ther (2010) 0.78
[Choosing between peritoneal dialysis and haemodialysis: a critical appraisal of the literature]. Nephrol Ther (2005) 0.77
[Secondary hyperparathyroidism and anemia. Effects of a calcimimetic on the control of anemia in chronic hemodialysed patients. Pilot Study]. Nephrol Ther (2011) 0.77
A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension. Curr Med Res Opin (2006) 0.77
Sodium intake and blood pressure in healthy individuals. J Hypertens (2003) 0.76
Dynamic renal blood flow measurement by positron emission tomography in patients with CRF. Am J Kidney Dis (2002) 0.76
Stress-induced renal alterations in normotensives offspring of hypertensives and in hypertensives. Am J Hypertens (2002) 0.76
Intermediate-dose (25mg/m2) IV melphalan for multiple myeloma with renal failure. J Nephrol (2002) 0.75
Advances in anabolic interventions for malnourished dialysis patients. J Ren Nutr (2003) 0.75
[Proteinuria]. Nephrol Ther (2006) 0.75
[In Process Citation]. Bull Acad Natl Med (2016) 0.75
[Hypertension in blacks]. Presse Med (2006) 0.75
Use of a collaborative database for epidemiological analyses and professional practice evaluation. J Eval Clin Pract (2011) 0.75
[Evaluation of renal oxygen content by BOLD MRI]. Nephrol Ther (2012) 0.75
[The États Généraux du Rein, a unique opportunity for the French nephrology]. Nephrol Ther (2012) 0.75
Preventing acute decrease in renal function induced by coronary angiography (PRECORD): a prospective randomized trial. Arch Cardiovasc Dis (2009) 0.75
[Funding research in nephrology: the essential partnership between scientific societies and Kidney Foundation]. Nephrol Ther (2013) 0.75
[Home hemodialysis: the technical overview. A 2010 survey]. Nephrol Ther (2012) 0.75
Recurrent idiopathic thrombotic thrombocytopenic purpura: a role for vaccination in disease relapse? Am J Kidney Dis (2006) 0.75